Esperion Therapeutics, Inc.
NASDAQ: ESPR0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Sheldon L. Koenig
- Employees
- 304
- Headquarters
- Ann Arbor, United States
- IPO year
- 2013
- Market cap
- $654.9M
- Website
- https://www.esperion.com
Loading ESPR…
Loading profile data…Frequently asked questions about ESPR
What does Esperion Therapeutics, Inc. (ESPR) do?
Esperion Therapeutics, Inc. operates as a pharmaceutical firm, concentrating on the development and commercialization of treatments for individuals with high levels of low-density lipoprotein (LDL) cholesterol. The company's flagship pharmaceutical products are NEXLETOL (bempedoic acid) and NEXLIZET (a tablet combining bempedoic acid and ezetimi...
Where does ESPR trade?
Esperion Therapeutics, Inc. (ESPR) trades on the NASDAQ Global Market.
What sector is ESPR in?
Esperion Therapeutics, Inc. (ESPR) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Esperion Therapeutics, Inc.?
Sheldon L. Koenig is the chief executive officer of Esperion Therapeutics, Inc. (ESPR).
Where is Esperion Therapeutics, Inc. headquartered?
Esperion Therapeutics, Inc. is headquartered in United States.
Does ESPR pay a dividend?
Esperion Therapeutics, Inc. (ESPR) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ESPR go public?
Esperion Therapeutics, Inc. (ESPR) completed its initial public offering in 2013.